3 results
Not approvedWill not start
Primary* To compare TFFS of patients with progressive, advanced, kinase inhibitor naïve, RET-mutant MTC treated with LOXO-292 versus cabozantinib or vandetanib.Secondary* To compare other efficacy outcomes, based on RECIST 1.1 criteria, observed in…
Approved WMORecruiting
Study CA001-050 is a Phase 2 randomized, open label, multicenter clinical study designed to assess the safety and tolerability, of treatment with MS-986012 in combination with chemotherapy (carboplatin and etoposide) and nivolumab when administered…
Approved WMORecruiting
To compare PFS of patients with progressive, advanced, kinase inhibitor naïve, RET-mutant MTC treated with selpercatinib versus cabozantinib or vandetanib.